Dr David Dodwell
Contact information
| david.dodwell@ndph.ox.ac.uk | |
| Tel | 01865 43562 |
David Dodwell
BSc, MD, FRCP, FRCR
Senior Clinical Research Fellow
I am a senior breast oncologist based in Leeds with a number of research and governance activities. I am the lead oncologist on the Sloane, NHS screening & national HQIP breast cancer audits.
I am a senior clinical research fellow to the EBCTCG and a member of steering groups for 12 ongoing UK trials in breast cancer. I sit on the trial management committees for 3 trials.
I am UK lead for the SACT project (UK chemotherapy database) and chair the clinical group, which provides input and advice to this project to examine the safety, efficacy and cost-effectiveness of chemotherapy used in England.
Recent Publications
5-
Making progress in early breast cancer: Taking time or accepting risk?
Mannu GS. and Dodwell D., (2017), European Journal of Cancer, 78, 24 - 27
-
The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.
Maxwell AJ. et al, (2016), Breast (Edinburgh, Scotland), 27, 109 - 115
-
Adjuvant treatment for breast cancer
Flatley MJ. and Dodwell DJ., (2016), Surgery (United Kingdom), 34, 43 - 46
-
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Waters SH. et al, (2009), Cancer Chemother Pharmacol, 64, 407 - 412
-
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Johnston SR. et al, (2008), Breast Cancer Res Treat, 110, 327 - 335